June 29, 2012
Connie K. Ho for redOrbit.com Your Universe Online
In 1993, the autosomal dominant gene mutation responsible for Huntingtons Disease (HD) was discovered. However, no treatments are known to slow its progression. New research may pave the way to better understanding of the disease. Researchers at Johns Hopkins recently announced that they were able to produce stem cells from skin cells from a person who had severe, early-onset form of HD; the cells were then changed into neurons that degenerated like the cells affected by HD.
The research was recently published in the journal Cell Stem Cell. The investigators worked with an international consortium in creating HD in a dish. The group was made up of scientists from Johns Hopkins University School of Medicine, Cedars-Sinai Medical Center, the University of California at Irvine, as well as six other groups. The team looked at many other HD cell lines and control cell lines to verify that the results were consistent and reproducible in other labs. The investigators believe that the findings allow them to better understand and eliminate cells in people in with HD. They hope to study the effects of possible drug treatments on cells that would be otherwise found deep in the brain.
Having these cells will allow us to screen for therapeutics in a way we havent been able to before in Huntingtons disease, remarked lead researcher Dr. Christopher A. Ross, a professor of psychiatry and behavioral sciences, neurology, pharmacology and neuroscience at the Johns Hopkins University School of Medicine, in a prepared statement. For the first time, we will be able to study how drugs work on human HD neurons and hopefully take those findings directly to the clinic.
The team of researchers is studying small molecules for the ability to block HD iPSC degeneration to see if they can be developed into new drugs for HD. As well, the ability to produce from stem cells the same neurons found in HD may have effects for similar research in other neurodegenerative diseases like Alzheimers and Parkinsons. In the experiment, Ross took a skin biopsy from a patient with very early onset HD. The patient was seven years old at the time, with a severe form of disease and a mutation that caused it. By using cells from a patient who had quickly progressing HD, Ross team were able to mimic HD in a way that could be used by patients who had different forms of HD.
The skin cells were grown in culture and reprogrammed to induce stem cells that were pluripotent. Then, another cell line was created in the same way from someone who didnt have HD. The other HD and control iPS cells were produced as part of the NINDS funded HD iPS cell consortium. Investigators from Johns Hopkins and the other consortium labs changed the cells into typical neurons and then into medium spiny neurons. The process took a total of three months and the scientists found the medium spiny neurons from the HD cells acted how the medium spiny neurons form an HD patient would. The cells demonstrated quick degeneration when cultured in the lab with a basic culture medium that didnt include extensive supporting nutrients. On the other hand, control cell lines didnt demonstrate neuronal degeneration.
These HD cells acted just as we were hoping, says Ross, director of the Baltimore Huntingtons Disease Center. A lot of people said, Youll never be able to get a model in a dish of a human neurodegenerative disease like this. Now, we have them where we can really study and manipulate them, and try to cure them of this horrible disease. The fact that we are able to do this at all still amazes us.
Source: Connie K. Ho for redOrbit.com Your Universe Online
Read more:
Skin Cells Create Stem Cells In Huntington Disease Study
- Selma Blair Shares That Shes Now in Remission 3 Years After MS Diagnosis - Self - August 18th, 2021
- Third dose of COVID-19 vaccine to be offered to certain residents - Martins Ferry Times Leader - August 18th, 2021
- Friends, family continue Jocelyn's drive to increase stem cell donors - Chatham This Week - August 18th, 2021
- Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy... - August 18th, 2021
- LSU Health Shreveport Vaccine Clinic at 2726 Linwood Avenue to Begin Administering Third Doses of Vaccine Tomorrow for Those Who Meet CDC Requirements... - August 18th, 2021
- Eagle County begins offering third vaccine doses to the immunocompromised - Vail Daily News - August 18th, 2021
- CDC: Third Dose Of COVID-19 Vaccine Recommended For Moderately & Severely Immunocompromised Individuals Only - KSST - August 18th, 2021
- New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff - FierceBiotech - July 22nd, 2021
- Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team - Yahoo Finance - July 22nd, 2021
- For Patients with HIV and Cancer, a Multidisciplinary Treatment Approach is Critical - Targeted Oncology - July 22nd, 2021
- Keeping the physical appointment was critical, the show of support appreciated by Renville County Commissioner - West Central Tribune - May 15th, 2021
- Appia Bio aims for a new kind of off-the-shelf CAR-T with $52M raise - FierceBiotech - May 15th, 2021
- Experimental treatments risk further medicalisation of menopause - The BMJ - May 15th, 2021
- Biopreservation Market Know the diverse technological advancements in the biopreservation - BioSpace - May 15th, 2021
- Reawakened immune cells attack cells tied to diseases of aging - STAT - STAT - May 15th, 2021
- Global Stem Cell Therapy Market Analysis and Forecast (2019-2024) The Courier - The Courier - May 3rd, 2021
- Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic - BioSpace - March 8th, 2021
- Retracing the Lineage of Cancer Cells - Technology Networks - March 8th, 2021
- QC Kinetix (Myrtle Beach) Offers Stem Cells Therapy, An Alternative to Surgery For Pain Management in Myrtle Beach, SC - Press Release - Digital... - March 8th, 2021
- Caribou nets $115M to boost CRISPR tech, advance off-the-shelf cell therapies - FierceBiotech - March 8th, 2021
- QC Kinetix (San Antonio) Offers Non-Surgical Regeneration Therapy To Treat Aches, Pains, and Injuries In Individuals Around San Antonio - Press... - March 8th, 2021
- New Research Study Investigates Metformin as a Therapy to Promote Brain Repair and Reduce Disability in Children and Young Adults with MS -... - February 2nd, 2021
- #FillTheSeats to save lives this February with Canadian Blood Services - Sportsnet.ca - January 30th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 30th, 2021
- ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -... - January 30th, 2021
- Cell Therapy Market 2020 Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025 KSU | The Sentinel Newspaper - KSU | The... - January 30th, 2021
- TScan Moves Toward the Clinic with $100 Million Series C Round - BioSpace - January 30th, 2021
- Love Your Skin: What Is SPF And Why Is It Important? - Yahoo Movies Canada - January 30th, 2021
- Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction - Cath Lab... - January 30th, 2021
- From hacking the immune system at the Parker Institute to decoding and reprogramming human cells - leading clinical immunotherapies developer Ramy Ibr... - January 30th, 2021
- City Awards $38 Million in Infrastructure Grants for City Science Institutions - CityLand CityLand - CityLand - January 30th, 2021
- Mesoblast Limited: Is Stemcell Therapy Ready For Prime Time? - Sick Economics - January 22nd, 2021
- Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction | DNA RNA... - January 22nd, 2021
- Breakthrough motor neurone disease study finds way to reverse damage - The National - January 19th, 2021
- Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene... - January 12th, 2021
- Cancer Stem Cell Therapy Market : Information, Figures And Analytical Insights 2020-2026 - LionLowdown - January 5th, 2021
- Paint it all Pink winner charity donation helps Elizabeth Wende Breast Care Fund - MPNnow.com - December 22nd, 2020
- Center for Regenerative Medicine - Mayo Clinic - December 17th, 2020
- Cancer Stem Cell Therapy Market Revenue, Global Forecast, Cost, Key Participants and Emerging Trends and Key Players-AVIVA BioSciences , AdnaGen - The... - December 12th, 2020
- Cancer Stem Cell Therapy Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Cheshire Media - December 5th, 2020
- Short Redhead Reel Reviews for the week of Dec. 4 - ECM Publishers - December 5th, 2020
- Human sperm stem cells grown in lab, an early step toward infertility treatment - Jill Lopez - November 18th, 2020
- Global Stem Cell and Primary Cell Culture Medium Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research... - November 18th, 2020
- Updated: FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial - Endpoints News - November 18th, 2020
- FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology - BioSpace - November 16th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 16th, 2020
- Global Cancer Stem Cell Therapy Market Outlook by Types, Applications, End Users and Opportunities to 2025 - TechnoWeekly - November 16th, 2020
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire - November 3rd, 2020
- What's On The Ballot? Here's A Look At California's 2020 Propositions - KPBS - November 3rd, 2020
- The Animal Stem Cell Therapy market to witness remarkable disruptions in the next decade - TechnoWeekly - October 28th, 2020
- Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL - OncLive - October 28th, 2020
- Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn's Disease and Ulcerative Colitis -... - October 24th, 2020
- Stem cells, repair cells, & growth factors: What is the latest? - The Times of India Blog - October 20th, 2020
- Cell Therapy Market Trend,COVID-19 Impact,Current Industry Figures With Demand By Countries And Future Growth - PRnews Leader - October 20th, 2020
- Global and United States Cancer Stem Cell Therapy Market Leading Players Expected to Witness the Highest Growth 2025 | AVIVA BioSciences, AdnaGen,... - October 20th, 2020
- Stem Cell and Primary Cell Culture Medium Market Share, By Product Analysis, Ap - News by aeresearch - October 20th, 2020
- Months after achieving unicorn status, Orca steers into the fast lane with an RMAT designation for cell therapy candidate - Endpoints News - October 15th, 2020
- EdiGene Gets $67 Million Infusion to Bring Gene Editing to the Clinic - BioSpace - October 15th, 2020
- CAR T-cell Therapies for the Treatment of Patients with Acute Lymphoblastic Leukemia - OncoZine - October 15th, 2020
- Bone Therapeutics' allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion -... - October 15th, 2020
- Biopharma Money on the Move: October 7-14 - BioSpace - October 15th, 2020
- Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. - UroToday - October 8th, 2020
- Around Town: Life is a series of choices a look at California's ballot propositions - VVdailypress.com - October 8th, 2020
- League of Women Voters Releases Their Proposition recommendations - Valley Voice - October 8th, 2020
- Expansion Therapeutics Names Renato Skerlj, Ph.D., Chief Executive Officer and President - BioSpace - October 8th, 2020
- What is the difference between ventilation and respiration? - EMS1.com - October 8th, 2020
- Props to you, Californians: A preview of what's on your November ballot - Palo Alto Online - October 8th, 2020
- TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for... - October 8th, 2020
- How to Vote This November: A Progressive's Opinion Redheaded Blackbelt - Redheaded Blackbelt - October 1st, 2020
- Cancer Stem Cell Therapy Market Size is Thriving worldwide with Topmost Companies Like: Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem... - September 30th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - The Daily Chronicle - September 25th, 2020
- Global Stem Cell and Primary Cell Culture Medium Market Research (2015-2026): In-depth Assessment of the Growth and other Aspects - Internet Shots - September 23rd, 2020
- Cellular Therapy Products Market 2020 2025 analysis examined in new C - News by aeresearch - September 23rd, 2020
- Those linked to stem cell board received more than $2.1 billion - Capitol Weekly - September 15th, 2020
- Takeda Expands Cell Therapy Efforts with New R&D; Manufacturing Plant in Boston - BioSpace - September 15th, 2020
- Allow your body to heal on its own with the help of Stemcure Clinic - Lowvelder - September 15th, 2020
- The Animal Stem Cell Therapy market to Undergo positive Transformation between 2017 and 2025 - The Daily Chronicle - September 12th, 2020
- Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL - OncLive - September 12th, 2020
- When old age catches up with you in your 30s - The Standard - August 31st, 2020
- The 9th ISS R&D; Conference Is Opening This Week, but This Year's Setup Is Different - Science Times - August 31st, 2020
